Evidence map›Paper›PMID 36134366›Full record

ArticleNanoscale advances2022

Graphene-based phenformin carriers for cancer cell treatment: a comparative study between oxidized and pegylated pristine graphene in human cells and zebrafish.

Abdelnour Alhourani, Jan-Lukas Førde, Mojdeh Nasrollahzadeh, Lutz Andreas Eichacker, Lars Herfindal, Hanne Røland Hagland

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Abdelnour AlhouraniDepartment of Chemistry, Biosciences and Environmental Engineering, University of Stavanger Stavanger Norway hanne.r.hagland@uis.no.ORCID https://orcid.org/0000-0003-0620-8083
Jan-Lukas FørdeCentre for Pharmacy, Department of Clinical Science, University of Bergen Bergen Norway.ORCID https://orcid.org/0000-0002-3172-5608
Mojdeh NasrollahzadehDepartment of Chemistry, Biosciences and Environmental Engineering, University of Stavanger Stavanger Norway hanne.r.hagland@uis.no.
Lutz Andreas EichackerDepartment of Chemistry, Biosciences and Environmental Engineering, University of Stavanger Stavanger Norway hanne.r.hagland@uis.no.
Lars HerfindalCentre for Pharmacy, Department of Clinical Science, University of Bergen Bergen Norway.
Hanne Røland HaglandDepartment of Chemistry, Biosciences and Environmental Engineering, University of Stavanger Stavanger Norway hanne.r.hagland@uis.no.ORCID https://orcid.org/0000-0002-7470-1358
University of Stavanger · NOHaukeland University Hospital · NOUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graphene is an attractive choice for the development of an effective drug carrier in cancer treatment due to its high adsorption area and pH-responsive drug affinity. In combination with the highly potent metabolic drug phenformin, increased doses could be efficiently delivered to cancer cells. This study compares the use of graphene oxide (GO) and polyethylene glycol stabilized (PEGylated) pristine graphene nanosheets (PGNSs) for drug delivery applications with phenformin. The cytotoxicity and mitotoxicity of the graphene-based systems were assessed in human cells and zebrafish larvae. Targeted drug release from GO and PGNSs was evaluated at different pH levels known to arise in proliferating tumor microenvironments. PGNSs were less cytotoxic and mitotoxic than GO, and showed an increased release of phenformin at lower pH in cells, compared to GO. In addition, the systemic phenformin effect was mitigated in zebrafish larvae when bound to GO and PGNSs compared to free phenformin, as measured by flavin metabolic lifetime imaging. These results pave the way for improved phenformin-based cancer therapy using graphene nano-sheets, where PGNSs were superior to GO.

Identifiers

PMID36134366
PMCPMC9417205
OpenAlexW4211112693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.